(S)-Thalidomide
Based on 1 Customer Validation
(S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN) .
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.52%
- CAS No.: 841-67-8
- 화학식: C13H10N2O4
- 분자량:258.23
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Autophagy Compound Library
HY-L029
-
Ubiquitination Compound Library
HY-L050
-
E3 Ligase Ligand Library
HY-L128
-
Molecular Glue Compound Library
HY-L137
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
-
Molecular Glue-like Compound Library
HY-L918
Biological Activity
|
Cereblon |
(S)-Thalidomide treatment results in a reduction in cell viability in U266 cells with an IC50 of 362 μM[1].
(S)-Thalidomide treatment increased apoptosis in a dose-dependent manner in U266 cells[1].
There are changes in the expression profile of genes involved in angiogenesis and apoptosis, but the changes are most dramatic in the apoptotic genes. In particular, the expression of I-κB kinase is decreased by two-fold, which is associated with a four-fold decrease in NF-κB expression. (S)-Thalidomide increases the Bax:Bcl-2 ratio, also increases I-kB protein levels, and decreases NF-kB activity. A dramatic decrease in Bcl-2 expression with (S)-Thalidomide suggests a possible enhancement of cytotoxic effect if combined with other cytotoxic agents[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U266 MM cells
-
Concentration:0 µM, 10 µM, 100 µM, 150 µM, 200 µM, 1000 µM
-
Incubation Time:3 days
-
Result:A reduction in cell viability was observed in U266 cells.
-
Cell Line:U266 MM cells
-
Concentration:100 µM, 150 µM, 200 µM, 1000 µM
-
Incubation Time:3 days
-
Result:Increased apoptosis in U266 cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 841-67-8
-
Appearance Solid
-
분자량 258.23
-
화학식 C13H10N2O4
-
Color Off-white to light brown
-
SMILES
O=C1N([C@@H](CC2)C(NC2=O)=O)C(C3=C1C=CC=C3)=O
-
Synonyms
(S)-(-)-Thalidomide
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
용액&용해도
DMSO : 83.33 mg/mL (322.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
-
Data Sheet (277 KB)
-
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
-
Handling Instructions (2659 KB)
References
[1]. Liu WM, et al. s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol J. 2004;5(3):247-54. [Content Brief]
[2]. Stephens TD. The effect of thalidomide in chicken embryos. Birth Defects Res A Clin Mol Teratol. 2009 Aug;85(8):725-31. [Content Brief]
[3]. Murphy S, et al. Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. J Pharm Pharmacol. 2007 Jan;59(1):105-14. [Content Brief]
[4]. Tokunaga E, et al. Understanding the Thalidomide Chirality in Biological Processes by the Self-disproportionation of Enantiomers. Sci Rep. 2018 Nov 20;8(1):17131. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.8725 mL | 19.3626 mL | 38.7252 mL | 96.8129 mL |
| 5 mM | 0.7745 mL | 3.8725 mL | 7.7450 mL | 19.3626 mL | |
| 10 mM | 0.3873 mL | 1.9363 mL | 3.8725 mL | 9.6813 mL | |
| 15 mM | 0.2582 mL | 1.2908 mL | 2.5817 mL | 6.4542 mL | |
| 20 mM | 0.1936 mL | 0.9681 mL | 1.9363 mL | 4.8406 mL | |
| 25 mM | 0.1549 mL | 0.7745 mL | 1.5490 mL | 3.8725 mL | |
| 30 mM | 0.1291 mL | 0.6454 mL | 1.2908 mL | 3.2271 mL | |
| 40 mM | 0.0968 mL | 0.4841 mL | 0.9681 mL | 2.4203 mL | |
| 50 mM | 0.0775 mL | 0.3873 mL | 0.7745 mL | 1.9363 mL | |
| 60 mM | 0.0645 mL | 0.3227 mL | 0.6454 mL | 1.6135 mL | |
| 80 mM | 0.0484 mL | 0.2420 mL | 0.4841 mL | 1.2102 mL | |
| 100 mM | 0.0387 mL | 0.1936 mL | 0.3873 mL | 0.9681 mL |
(S)-Thalidomide Related Classifications
HY-14658A Related Classifications
Powered by Bioz